This Article Full Text Full Text (PDF) Supplemental Data All Versions of this Article: 92/8/2977    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Aronne, L. Articles by Weyer, C. Search for Related Content PubMed PubMed Citation Articles by Aronne, L. Articles by Weyer, C. Related Collections Diabetes and Insulin Metabolism Obesity

Progressive Reduction in Body Weight after Treatment with the Amylin Analog Pramlintide in Obese Subjects: A Phase 2, Randomized, Placebo-Controlled, Dose-Escalation Study

Weill-Cornell Medical College (L.A.), New York, New York 10021; Scripps Clinic (K.F.), San Diego, California 92007; University of California, San Diego (V.A.), San Diego, California 92093; and Amylin Pharmaceuticals, Incorporated (K.C., A.H., N.C.K., C.B., C.W.L., C.W.), San Diego, California 92121

Address all correspondence and requests for reprints to: Christian Weyer, M.D., M.A.S., Executive Director, Clinical Research, Amylin Pharmaceuticals, Inc., 9360 Towne Centre Drive, San Diego, California 92121. E-mail: cweyer{at}amylin.com.

Context: In previous 1-yr trials, treatment with pramlintide (120 µg), an analog of the ß-cell hormone amylin, induced sustained reductions in A1C and body weight in insulin-using subjects with type 2 diabetes.

Objective: To assess the potential of pramlintide as an antiobesity agent, we assessed the weight effect, safety, and tolerability of pramlintide in non-insulin-treated obese subjects with and without type 2 diabetes at doses greater than previously studied.

Design/Setting: We performed a randomized, double-blind, placebo-controlled, multicenter study.

Patients: A total of 204 obese subjects [80/20% female/male, age 48 ± 10 yr, and body mass index 37.8 ± 5.6 kg/m² (mean ± SD)] participated in the study.

Intervention: For 16 wk, without concomitant lifestyle intervention, subjects self-administered pramlintide (nonforced dose escalation 240 µg) or placebo via sc injection three times a day before meals.

Main Outcome Measures: Weight, waist circumference, tolerability, and safety were the main outcome measures.

Results: Pramlintide was generally well tolerated, with 88% of subjects able to escalate to the maximum dose of 240 µg. Withdrawal rates were similar between placebo (25%) and pramlintide-treated subjects (29%). Subjects completing 16 wk of pramlintide treatment experienced placebo-corrected reductions in body weight of 3.7 ± 0.5% (3.6 ± 0.6 kg; P < 0.001) and waist circumference (3.6 ± 1.1 cm; P < 0.01). Approximately 31% of pramlintide-treated subjects achieved 5% weight loss (vs. 2% placebo; P < 0.001). More pramlintide than placebo-treated subjects reported improvements in appetite control (72% vs. 31%), weight control (63% vs. 24%), and overall well-being (52% vs. 17%). No unexpected safety signals were observed. The most common adverse event reported was mild, transient nausea. Pramlintide-treated subjects not reporting nausea experienced weight loss similar to those who did (3.6 ± 0.5% and 3.9 ± 0.5%, respectively).

Conclusion: These results support continued evaluation of pramlintide as a potential treatment for obesity.

This article has been cited by other articles:

				S. R. Smith, L. J. Aronne, C. M. Burns, N. C. Kesty, A. E. Halseth, and C. Weyer Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity Diabetes Care, September 1, 2008; 31(9): 1816 - 1823. [Abstract] [Full Text] [PDF]

				J. D. Roth, B. L. Roland, R. L. Cole, J. L. Trevaskis, C. Weyer, J. E. Koda, C. M. Anderson, D. G. Parkes, and A. D. Baron Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies PNAS, May 20, 2008; 105(20): 7257 - 7262. [Abstract] [Full Text] [PDF]

				J. J. Hwang, J. L. Chan, G. Ntali, D. Malkova, and C. S. Mantzoros Leptin Does Not Directly Regulate the Pancreatic Hormones Amylin and Pancreatic Polypeptide: Interventional studies in humans Diabetes Care, May 1, 2008; 31(5): 945 - 951. [Abstract] [Full Text] [PDF]

				S. V. Edelman Optimizing Diabetes Treatment Using an Amylin Analogue The Diabetes Educator, January 1, 2008; 34(1_suppl): 4S - 10S. [Abstract] [Full Text] [PDF]

				M. M. Huizinga Weight-Loss Pharmacotherapy: A Brief Review Clin. Diabetes, October 1, 2007; 25(4): 135 - 140. [Abstract] [Full Text] [PDF]